HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
VYGR
Voyager Therapeutics, Inc.
There isn't enough reported data to score VYGR yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
VYGR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Strong |
VYGR's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
VYGR PE Valuation
VYGR has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
VYGR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect VYGR's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over VYGR on earnings, with more consistent year-over-year improvement.
VYGR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.74 | +$0.42 |
| Q2 2026 | -$1.81 | +$0.04 |
| Q1 2026 | -$1.98 | -$0.52 |
| Q4 2025 | -$2.04 | -$0.91 |
| Q3 2025 | -$2.16 | -466% |
| Q2 2025 | -$1.85 | -1256% |
| Q1 2025 | -$1.46 | -$1.29 |
| Q4 2024 | -$1.13 | -138% |
VYGR is still losing money, but less than at its worst: $1.74 per share over the past year, against $2.45 at its worst in late 2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over VYGR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over VYGR on profitability, with a higher operating margin.
VYGR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4M | -70% |
| Q2 2026 | $3.2M | -39% |
| Q1 2026 | $2.6M | -60% |
| Q4 2025 | $15.3M | +144% |
| Q3 2025 | $13.4M | -46% |
| Q2 2025 | $5.2M | -82% |
| Q1 2025 | $6.5M | -67% |
| Q4 2024 | $6.3M | -93% |
VYGR's revenue has slid since its 2023 peak: $4M last quarter, down 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -658% | -429 points |
| Q2 2026 | -834% | -130 points |
| Q1 2026 | -1167% | -631 points |
| Q4 2025 | -195% | +415 points |
| Q3 2025 | -229% | -173 points |
| Q2 2025 | -704% | -654 points |
| Q1 2025 | -536% | -453 points |
| Q4 2024 | -610% | -670 points |
VYGR's operating margin was −658% last quarter, down 429 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over VYGR on cash generation, producing positive trailing cash flow while its opponent burns cash.
VYGR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.7M | +$11.6M |
| Q2 2026 | -$25.8M | +$8.5M |
| Q1 2026 | -$33.4M | +$5.1M |
| Q4 2025 | -$30.9M | -$16.2M |
| Q3 2025 | -$31.3M | -$3M |
| Q2 2025 | -$34.4M | -$1.8M |
| Q1 2025 | -$38.6M | -168% |
| Q4 2024 | -$14.7M | +$9.8M |
VYGR has burned cash in almost every quarter: −$110M over the past year, against −$119M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over VYGR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
VYGR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +1.3M shares |
| 1 year | +5.1% | +3M shares |
| 3 years | +41% | +18M shares |
| 5 years | +64% | +24M shares |
| Available history | +72% | +25.9M shares |
VYGR has 62M diluted shares, up 5.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
VYGR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -8.0x | Net Cash |
| Q4 2023 | -0.5x | Net Cash |
| Q3 2023 | -1.4x | Net Cash |
| Q2 2023 | -2.6x | Net Cash |
| Q1 2023 | -2.7x | Net Cash |
| Q2 2021 | -10.6x | Net Cash |
| Q1 2021 | -3.9x | Net Cash |
| Q4 2020 | -3.4x | Net Cash |
VYGR has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
VYGR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.9 | Oversold |
| Stochastic | 4.6 | Oversold |
VYGR's weekly RSI is 27 (oversold) and its Stochastic is 5 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
VYGR PE vs Healthcare Sector
| Metric | VYGR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VYGR has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
VYGR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.06 | 17% below |
| 20 week MA | $2.81 | 40% below |
| 50 week MA | $3.45 | 51% below |
| 100 week MA | $3.74 | 55% below |
| 200 week MA | $5.97 | 72% below |
VYGR is in a downtrend: it's below all five of its weekly moving averages, and 72% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over VYGR on returns for 2026, with the stronger performance.
VYGR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.9 | $7.98 | -43% |
| 2021 | $7.98 | $2.93 | -63% |
| 2022 | $2.93 | $5.56 | +90% |
| 2023 | $5.56 | $8.44 | +52% |
| 2024 | $8.44 | $5.74 | -32% |
| 2025 | $5.74 | $4.08 | -29% |
| 2026 YTD | $4.08 | $1.70 | -58% |
VYGR has finished lower in four of the last six years. It's down 58% so far in 2026.